Chief Executive Officer, Moderna
Noubar Afeyan, Ph.D.
Co-Founder and Chairman, Moderna
Putting the Pieces in Place
On First Street in Cambridge, MA, Moderna takes shape with the vision that messenger RNA therapeutics™ technology — mRNA — could use a patient’s own cells to produce proteins that could prevent, treat and cure diseases. A board of directors is assembled, and Co-Founder Noubar Afeyan and his team hire Stéphane Bancel as CEO.
Hear from CEO Stéphane Bancel about Moderna’s evolution and how the company strives to be the best version of itself.
Can you guess what form
Moderna’s budget took at the time
of the AstraZeneca collaboration?
Get the inside scoop as
Goodwin’s Stuart Cable
shares one of his favorite
stories about this
The Power of Science:
What began as a startup just over a decade ago is now a household name. As we congratulate Moderna on the successful launch of its COVID-19 vaccine, we invite you to explore the company’s journey from the start.
Moderna grants AstraZeneca the right to acquire up to 40 pioneering mRNA therapeutics. The $240 million deal is the largest preclinical strategic collaboration in the pharmaceutical industry to date. Most importantly, it funds the use of mRNA technology to develop therapeutics for cardiometabolic diseases and cancer.
The Collaboration That Launched a Company
On the heels of the landmark AstraZeneca deal, Moderna raises $110 million in a financing round. Three years later, $474 million is raised and $500 million in equity financing follows. Support from U.S. and international institutional investors enables growth of the mRNA platform across diverse therapeutic areas.
Raising Critical Capital to Fund Pioneering R&D
2013, 2016, 2018
Built to advance its growing pipeline of mRNA medicines, Moderna opens a digitally-enabled and environmentally sustainable 200,000 sq. ft. clinical development manufacturing plant in Norwood, MA. The facility enables the company to control its supply chain and provide the necessary scale to support its work for decades to come.
End to End, One Step Closer to Industrialization
Moderna’s IPO exceeds the company’s revised goal of $600 million with an underwritten public offering of 17,600,000 shares of common stock at a public offering price of $23 per share. Moderna shares begin trading on Nasdaq (MRNA) with gross proceeds from the IPO reaching $1.34 billion.
The Largest Ever Biotechnology IPO
Learn the origin of Moderna’s ticker symbol as Goodwin’s Kingsley Taft revisits the day of this historic IPO.
A novel coronavirus is detected and spreads quickly, thrusting the world into a global pandemic.
Funding Critical Work to Stop the COVID-19 Virus
The Race to the Vaccine
The first participant is dosed in an NIH-led Phase 1 study of mRNA-1273 in March, and Moderna demonstrates its agility in progressing through the clinical trial phases quickly. The U.S. Food and Drug Administration grants Emergency Use Authorization in December, allowing the vaccine to be distributed in the U.S.
What was Noubar Afeyan’s reaction to learning about the vaccine’s successful clinical trial? Watch the video to find out.
What was it like negotiating commercial agreements for the Moderna vaccine with governments all over the world? Goodwin’s Sarah Solomon and Tim Worden share their experience in this video.
Moderna executives meet with prime ministers, governmental officials and supply chain partners from all over the world. Hundreds of millions of doses of mRNA-1273 are ordered globally, and the company establishes its own global distribution network to allow it to commercialize the vaccine without a large pharmaceutical partner.
Building the Plane While Flying It
As of February 2021, Moderna signs commercial supply agreements for hundreds of millions of mRNA-1273 doses across the globe. Hover over the map markers below to see where.
It is hoped that Moderna’s breakthrough mRNA modality will in time result in prophylactic vaccines and therapeutics being deployed across numerous indications and disease types — ranging from infectious to rare disease to oncology. The future is bright as mRNA technology propels Moderna in its quest to save even more patient lives.
A New Generation of Transformative Medicine
What’s the “software of life?” Hear from Goodwin’s Stuart Cable on how he believes Moderna will take its place in history.
This informational piece, which may be considered advertising under the ethical rules of certain jurisdictions, is provided on the understanding that it does not constitute the rendering of legal advice or other professional advice by Goodwin Procter or its lawyers. Prior results do not guarantee a similar outcome. Goodwin Procter is an international legal practice carried on by Goodwin Procter LLP and its affiliated entities. For further information about our offices and the regulatory regimes that apply to them, please refer to goodwinlaw.com/Legal-Notices. © 2021 Goodwin Procter. All rights reserved.
Explore additional information about our practice, including our full list of press releases, webinars, awards and rankings, thought leadership and upcoming events:
Goodwin’s fully-integrated Life Sciences practice is designed to help clients navigate the rapidly evolving demands by providing a unique “one-stop-shop” service, allowing us to seamlessly advise through all stages of the corporate lifecycle while guiding our clients’ strategic and business goals.
We are proud to have a dedicated team of life sciences lawyers located in the major innovation hubs across the United States, Europe and Asia, giving our team the unique ability to advise clients when and where our services are needed.
Click on the badges to learn more about Operation Warp Speed, BARDA and Moderna’s stock offerings.
Quickly springing into action to leverage its technology to develop a COVID-19 vaccine, mRNA-1273 is delivered from Moderna’s manufacturing facility in just 42 days from sequence selection. This urgent work is facilitated by two stock offerings and a grant from Operation Warp Speed and BARDA (the Biomedical Advanced Research and Development Authority).
Operation Warp Speed committed funding to vaccine developers toward R&D, manufacturing and distribution. BARDA selected the recipients.
Moderna offered shares of its common stock at $19 per share in February 2020, followed by a second offering in May at $76 per share. Combined gross proceeds were over $1.8 billion.
United States: 300 million doses (with option for additional 200 million doses)
Colombia: 10 million doses
Canada: 44 million doses
Japan: 50 million doses
South Korea: 40 million doses
Taiwan: 5 million doses
Israel: 6 million doses
Switzerland: 13.5 million doses
United Kingdom: 17 million doses
European Union: 310 million doses (with option for additional 150 million doses in 2022)
As of February 2021, Moderna signs commercial supply agreements for hundreds of millions of mRNA-1273 doses across the globe. Tap on the globe to see where.